New HIV Drug Has Potential for Weekly or Once-Yearly Dosing

One of the surprises at CROI 2016 was the first virological data from a new highly potent NRTI that in a slow-release formulation has the potential for annual dosing and that is undergoing research as both treatment and PrEP.In an oral late-breaker, Jay Grobler from Merck presented results from a dose-ranging study in macaques to develop a model for phase 1 studies with MK-8591 (EFdA).1Baseline
Source: Nelson Vergel's HIV Blog - Category: Infectious Diseases Authors: Source Type: blogs